Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia

Trial Profile

Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Cyclophosphamide (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Hydroxypropylcellulose (Primary) ; Mesna (Primary) ; T lymphocyte cell therapies (Primary)
  • Indications Aplastic anaemia; Cytopenia
  • Focus Therapeutic Use

Most Recent Events

  • 22 Aug 2024 Status changed to recruiting.
  • 17 Aug 2023 Status changed from recruiting to active, no longer recruiting.
  • 02 Feb 2021 Planned initiation date changed from 1 Sep 2020 to 1 Jan 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top